Tag: <span>Ophthalmic diseases</span>

Tag: Ophthalmic diseases

Sjögren’s Syndrome

Sjögren’s Syndrome Synonym(s) Sicca syndrome ORPHA378 ICD-10 H35.0 UMLS C1527336 MedDRA 10040767 Status Under evaluation What is Sjögren’s syndrome Sjögren’s syndrome is a chronic autoimmune disorder characterized by the triad of dry eyes (keratoconjunctiva sicca), sensation of oral dryness (xerostomia) and/or swelling of the salivary glands secondary to lymphocytic infiltration and destruction of the exocrine …

Retinitis pigmentosa

Retinitis Pigmentosa ORPHA791 ICD-10 H35.5 UMLS C0035334 MedDRA 10038914 Status Under evaluation What is retinitis pigmentosa Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of sight. In patients with retinitis pigmentosa, cells in the retina (the light-sensitive surface at the back of the eye) become damaged …

Ophthalmic diseases

Our synthetic neurotrophin mimetics are intended for treatment of corneal lesions, either spontaneous – the neurotrophic keratitis – or traumatic, or even iatrogenic, as is the case for laser treatment of miopy. In this connection, on 16/12/2014, our lead compound was designated as orphan drug for the treatment of neurotrophic …

Rare diseases

Rare diseases under evaluation Amyotrophic lateral sclerosis Synonym(s) Charcot disease, Lou Gehrig disease ORPHA378 ICD-10 G12.2 UMLS C1527336 MedDRA 10040767 Status Under evaluation Retinitis Pigmentosa ORPHA791 ICD-10 H35.5 UMLS C0035334  MedDRA 10038914 Status Under evaluation Sickle Cell Disease Synonym(s) Sickle Cell Anemia ORPHA232 ICD-10 D57.0 D57.1 D57.2 UMLS C0002895 MedDRA 10040641 Status Under evaluation Sjögren’s syndrome Synonym(s) Sicca syndrome ORPHA803 ICD-10 H35.0 UMLS C0002736 MedDRA 10002026 Status Under evaluation

Recordati receives Orphan Drug Designation for its investigational treatment for neurotrophic keratitis

Recordati today announced that the FDA has granted Orphan Drug Designation to Recordati Rare Disease’s investigational product REC 0559 for the treatment of neurotrophic keratitis. REC 0559 is a low molecular weight non-peptidic human nerve growth factor (NGF) mimetic currently under global development by Recordati. REC 0559 was licensed in …

Recordati licenses an innovative treatment for neurotrophic keratitis

Recordati announced the signing of an exclusive license agreement with MimeTech for the development and subsequent commercialization on a global basis of a low molecular weight peptidomimetic of human nerve growth factor (NGF) for the treatment of neurotrophic keratitis, which already received an Orphan Drug Designation in the EU. Additional …

“Udonitrectag” receives orphan drug designation from the European Commission for the treatment of neurotrophic keratitis

On 16/12/2014, orphan designation (EU/3/14/1400) was granted by the European Commission to MIMETECH S.r.l., Italy, for (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine for the treatment of neurotrophic keratitis. Patients with neurotrophic keratitis have lower than normal levels of growth factors that are normally supplied by the trigeminal nerve and which play an important role …

Neurotrophic keratitis

Neurotrophic Keratitis Synonym(s) Neurotrophic keratopathy ORPHA137596 ICD-10 H16.2 UMLS C0339296 MedDRA 10069732 Status In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on 13 November 2014 recommending the granting of this designation. What is neurotrophic keratitis? Neurotrophic keratitis is a condition of …